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i.org/1kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein
cholesterol (LDL-C) levels in patients with hypercholesterolemia. In this 24-week, multicenter,
double-blind, placebo-controlled, dose-ranging study (NCT01592240), subjects with LDL-C
levels ‡80 mg/dl on stable statin therapy were randomized to Q14 days subcutaneous placebo
or bococizumab 50, 100, or 150 mg or Q28 days subcutaneous placebo or bococizumab 200 or
300 mg. Doses of bococizumab were reduced if LDL-C levels persistently decreased to £25 mg/
dl. The primary end point was the absolute change in LDL-C levels from baseline to week 12
after placebo or bococizumab administration. Continuation of bococizumab administration
through to week 24 enabled the collection of safety data over an extended period. Of the 354
subjects randomized, 351 received treatment (placebo [n[ 100] or bococizumab [n[ 251]).
The most efﬁcacious bococizumab doses were 150 mg Q14 days and 300 mg Q28 days.
Compared with placebo, bococizumab 150 mg Q14 days reduced LDL-C at week 12 by
53.4 mg/dl and bococizumab 300 mg Q28 days reduced LDL-C by 44.9 mg/dl; this was despite
dose reductions in 32.5% and 34.2% of subjects at week 10 or 8, respectively. Pharmacokinetic/
pharmacodynamic model-based simulation assuming no dose reductions predicted that boco-
cizumab would lower LDL-C levels by 72.2 and 55.4 mg/dl, respectively. Adverse events were
similar across placebo and bococizumab groups. Few subjects (n [ 7; 2%) discontinued
treatment because of treatment-related adverse events. In conclusion, bococizumab signiﬁcantly
reduced LDL-C across all doses despite dose reductions in many subjects. Model-based simu-
lations predicted greater LDL-C reduction in the absence of bococizumab dose reduction. The
Q14 days regimen is being evaluated in phase 3 clinical trials.  2015 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2015;115:1212e1221)The serine protease proprotein convertase subtilisin/kexin
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0.1016/j.amjcard.2015.02.006degradation.1 LDL uptake is reduced, resulting in higher
circulating levels of low-density lipoprotein cholesterol
(LDL-C).1 Gain-of-function mutations in PCSK9 increase
LDL-C levels and the risk of cardiovascular events.2
Conversely, loss-of-function PCSK9 mutations decrease
plasma LDL-C and cardiovascular risk.3 Bococizumab
(RN316/PF-04950615) is a humanized IgG2Da monoclonal
antibody (mAb) that recognizes and binds to the LDLR-
binding domain of PCSK9, thus preventing PCSK9-mediated
degradation of LDLR, leading to improved LDL clearance
and reduction of serum LDL-C levels.4 In phase 1 and 2a
clinical trials in hypercholesterolemic subjects, bococizumab
reduced LDL-C levels by up tow75% and was generally well
tolerated with few subjects discontinuing treatment because of
adverse events (AEs).5 This dose-ranging phase 2b study
evaluated the LDL-Celowering effect of subcutaneous doses
of bococizumab administered every 2 weeks (Q14 days) or
monthly (Q28days).A unique aspect of the trial designwas the
incorporation of bococizumab dose reductions if persistent
LDL-C values 25 mg/dl were achieved. To our knowledge,
this is the ﬁrst study of a PCSK9 inhibitor to report the impactwww.ajconline.org
Figure 1. Patient ﬂowchart. Subject allocation and disposition are shown for each of the bococizumab regimens, Q14 days and Q28 days.
Table 1
Baseline characteristics of all subjects randomized to placebo or bococizumab dosed every 14 days or every 28 days
Variable Q14 days Q28 days
Placebo*
(n ¼ 50)
Bococizumab (mg) Placebo
(n ¼ 51)
Bococizumab (mg)
50
(n ¼ 50)
100*
(n ¼ 52)
150*
(n ¼ 50)
200
(n ¼ 50)
300
(n ¼ 51)
Age (years) 61  10 59  11 62  10 61  10 58  12 60  10 60  8
Male 25 (50%) 24 (48%) 26 (50%) 21 (42%) 29 (57%) 19 (38%) 25 (49%)
White 39 (78%) 33 (66%) 37 (71%) 36 (72%) 35 (69%) 39 (78%) 41 (80%)
Black 9 (18%) 15 (30%) 12 (23%) 10 (20%) 14 (27%) 9 (18%) 8 (16%)
Asian and other 2 (4%) 2 (4%) 3 (6%) 4 (8%) 2 (4%) 2 (4%) 2 (4%)
Weight (kg) 91  22 91  24 90  21 90  17 91  21 88  24 89  19
BMI (kg/m2) 32  7 32  8 32  7 32  6 31  6 31  7 31  6
LDL-C (mg/dl) 109  32† 108  20 113  26† 106  18† 119  45 106  23 105  22
TC (mg/dl) 189  35† 186  35 195  34† 189  25† 198  45 185  30 179  30
TG (mg/dl) 124 (82, 180)† 109 (71, 155) 135 (96, 176)† 138 (100, 172)† 109 (80, 169) 123 (89, 158) 113 (79, 149)
NoneHDL-C (mg/dl) 137  34† 134  36 143  31† 136  23† 146  45 133  27 130  29
HDL-C (mg/dl) 52  14† 52  16 51  14† 53  14† 53  12 52  14 49  13
ApoB (mg/dl) 92  20† 89  22 97  17† 90  16† 97  28 91  16 87  16
ApoA-I (mg/dl) 151  25† 148  24 149  25† 151  30† 150  22 151  26 145  25
Lp(a) (mg/dl) 17 (5, 62)† 25 (8, 64) 18 (6, 66)† 22 (7, 86)† 18 (8, 48) 15 (5, 60) 31 (7, 60)
PCSK9 (ng/ml) 305 (260, 344)† 298 (257, 329)z 314 (238, 363)z 339 (308, 400)z 301 (233, 349)† 317 (271, 378)† 299 (252, 364)
Baseline statin dosex
Low 26 (52%) 25 (50%) 22 (42%) 20 (40%) 28 (55%) 23 (46%)† 22 (43%)†
High 24 (48%) 25 (50%) 30 (58%) 30 (60%) 23 (45%) 26 (52%)† 28 (55%)†
Values are mean  SD, median (Q1, Q3), or n (%).
ApoA-I ¼ apolipoprotein A-I; apoB ¼ apolipoprotein B; BMI ¼ body mass index; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density
lipoprotein cholesterol; Lp(a) ¼ lipoprotein(a); n ¼ number of subjects randomized; SD ¼ standard deviation; TC ¼ total cholesterol; TG ¼ triglycerides.
* Three subjects (1 each from the placebo, 100-mg, and 150-mg Q14 days groups) were randomized but did not receive treatment.
† Data are missing for 1 subject in each of these groups.
z Data are missing for 2 subjects in each of these groups.
x Low statin dose deﬁned as atorvastatin 10 mg, rosuvastatin5 mg, simvastatin20 mg, pravastatin40 mg, lovastatin80 mg, and ﬂuvastatin40 mg
daily; high statin dose deﬁned as all higher doses of these statins.
Preventive Cardiology/Bococizumab Therapy in Statin-Treated Patients 1213on LDL-C reduction when a dose reduction strategy is used
in an effort to prevent extremely low levels of LDL-C. This
report is the ﬁrst full publication of bococizumab data from the
phase 2 clinical trial program.
Methods
A more detailed description on the inclusion and exclusion
criteria, study design, dose selection, drug administration, andlaboratory evaluations can be found in the Supplementary
Methods.
Enrolled subjects included men and women 18 years
with hypercholesterolemia, on stable statin therapy
(>6 weeks before screening), with a fasting LDL-C
80 mg/dl, and triglycerides 400 mg/dl. Subjects were
excluded if they had a cardiovascular event during the pre-
vious 6 months, received treatment with systemic cortico-
steroids or an mAb during the previous 6 months, had
Figure 2. Mean absolute change from baseline in LDL-C at week 12. The
placebo and bococizumab Q14 days and Q28 days dose groups are shown,
with the corresponding mean percent changes from baseline in italics.
1214 The American Journal of Cardiology (www.ajconline.org)congestive heart failure (New York Heart Association class
III or IV), poorly controlled diabetesmellitus or hypertension,
or diagnosis of cancer, human immunodeﬁciency virus, or
other serious diseases.
This 24-week, multicenter, randomized, double-blind,
placebo-controlled, parallel-group, dose-ranging phase 2b
study (NCT01592240) was conducted from July 2012 to
May 2013. Subjects were randomized using an Interactive
Voice Response System in a 1:1:1:1:1:1:1 ratio to Q14 days
subcutaneous placebo or bococizumab 50, 100, or 150 mg or
Q28 days subcutaneous placebo or bococizumab 200 or
300 mg. Follow-up was for 6 to 8 weeks after the last dose of
study drug. For both the Q14 days and Q28 days regimens,
the bococizumab dose was reduced if LDL-C levels decreased
to 25 mg/dl: the ﬁrst dose reduction required 2 consecutive
LDL-C levels25 mg/dl; all further dose reductions required
1 LDL-C level 25 mg/dl. LDL-C data collected at 14 days
after the dose provided information on whether dose reduc-
tion of bococizumab was required. For the Q14 days regimen,
day 43 was the ﬁrst opportunity for dose reduction. The
bococizumab dose reduction sequence for this cohort was
150 mg / 100 mg / 50 mg / 25 mg / placebo or
100 mg/ 50 mg/ 25 mg/ placebo or 50 mg/ 25 mg
/ placebo. For the Q28 days regimen, day 57 was the
ﬁrst opportunity for dose reduction. The bococizumab dose
reduction sequence for this cohort was 300mg/ 200mg/
100 mg / 50 mg / placebo or 200 mg / 100 mg /
50 mg / placebo (Supplementary Figures 1 and 2). The
study was conducted under the guidelines of the Declaration
of Helsinki and the GoodClinical Practice requirements of the
International Conference on Harmonization. Local institu-
tional review boards approved the protocol, and all subjects
provided written informed consent. An independent data
monitoring committee reviewed all study data.
The primary end point was the absolute change in LDL-C
from baseline to week 12 after treatment with placebo or
bococizumab, with the primary statistical analysis reporting this
change as the placebo-adjusted treatment difference. Secondary
end points included percentage change in LDL-C and absolutechange and percentage change in non-HDL-C, HDL-C, total
cholesterol, triglycerides, apolipoprotein (apo) A-I, apoB, and
lipoprotein (a) from baseline at 12 and 24 weeks. The average
placebo-adjusted change in LDL-C from weeks 10 to 12 in the
Q28 days bococizumab dose groups was assessed as a tertiary
end point. Safety end points included the incidence of AEs,
serious AEs, laboratory abnormalities, incidence of antidrug
antibodies (ADAs), and injection site reactions through to week
24 and up to 8weeks of post-treatment follow-up.Bococizumab
dose groups were compared with their respective placebo group
using a mixed-model repeated measures analysis with the
dependent variable being change from baseline (in LDL-C for
the primary analysis) and including the ﬁxed-effect terms
treatment group, study visit time point, baseline value,
treatment  study visit time point interaction, and baseline
value  study visit time point interaction. An unstructured
covariance matrix was used for the within-subject errors. The
full analysis set population included all randomized subjects.
However, the mixed-model repeated measures used for the
statistical analyses of efﬁcacy data only incorporated subjects
who had a baseline and at least 1 postbaseline efﬁcacy mea-
surement. The analyses of safety data included all subjects who
had received at least 1 dose of studymedication. For all efﬁcacy
analyses, subjects remained in the dose group to which they
were randomized, regardless of any subsequent dose reductions.
Demographic and baseline data were summarized as mean
 SD for continuous variables with the exception of triglyc-
eride, lipoprotein (a), and PCSK9 values, which were not
normally distributed and, therefore, presented as median (Q1
and Q3), and n (%) for categorical variables. Total cholesterol
and triglyceride levels were assayed using standard enzymatic
methods. LDL-C was measured by Friedewald and reﬂex
ultracentrifugation for LDL-C levels 25 mg/dl.
Because of protocol-stipulated dose reductions of
bococizumab in this study, a population pharmacokinetic/
pharmacodynamic (PK/PD) model6 was developed using data
from 7 phase 1 and phase 2 clinical studies to construct a
predictor of bococizumab LDL-C lowering in the absence of
dose reductions. The population PK/PD data set consisted of
7,574 bococizumab PK observations and 10,177 LDL-C
measurements from 674 subjects. The model accounted for
dose interruptions or dose reductions implemented in the phase
2 trials and anymissed doses that may have occurred during the
trials. A 2-compartment PK model with parallel ﬁrst-order and
nonlinear (Michaelis-Menten) elimination was linked to an
indirect PD response model describing LDL-C response. Per-
formance of the ﬁnal PK/PD model was veriﬁed with model
diagnostics and visual predictive checks and was found to
accurately capture the observed pharmacokinetics of bococi-
zumab and LDL-C response in all studies and in this phase 2b
study, which included dose reductions triggered by LDL-C
levels 25 mg/dl. Clinical trial simulations using subject
demography data from this study were performed with the ﬁnal
PK/PD model to estimate the expected LDL-C response in this
phase 2b study assuming no missed doses or dose reductions.
Results
A total of 354 subjects were randomized and 351
received treatment with either placebo (n ¼ 100) or boco-
cizumab (n ¼ 251) (Figure 1). The 3 subjects who were
Table 2
Lipid efﬁcacy outcomes from baseline at week 12 in subjects randomized to placebo or bococizumab dosed every 14 days or every 28 days*
Variable Q14 days Q28 days
Placebo
(n ¼ 47)
Bococizumab (mg) Placebo
(n ¼ 46e47)
Bococizumab (mg)
50
(n ¼ 43e44)
100
(n ¼ 42e44)
150
(n ¼ 46)
200
(n ¼ 48)
300
(n ¼ 50)
LDL-C
Mean (SD)
change, mg/dl
e2.8 (29.2) e35.4 (26.6) e52.3 (31.3) e54.2 (27.0) e1.3 (37.2) e21.3 (28.0) e38.3 (41.3)
Mean (95% CI)
placebo-
adjusted
change, mg/dl
— e34.3
(e45.1, e23.5)
e45.1
(e55.9, e34.2)
e53.4
(e64.1, e42.7)
— e27.6
(e40.5, e14.7)
e44.9
(e57.7, e32.1)
P-value — <0.001 <0.001 <0.001 — <0.001 <0.001
Mean (SD)
percent
change, %
0.6 (25.5) e33.6 (23.3) e44.9 (23.4) e52.0 (24.7) 3.3 (25.0) e19.5 (26.6) e33.3 (35.2)
Mean (95% CI)
placebo-
adjusted
percent
change, %
— e35.0
(e44.9, e25.1)
e42.3
(e52.3, e32.3)
e53.1
(e63.0, e43.3)
— e27.0
(e38.3, e15.7)
e41.1
(e52.3, e29.9)
P-value — <0.001 <0.001 <0.001 — <0.001 <0.001
Total cholesterol
Mean (SD)
change, mg/dl
e5.6 (29.6) e35.8 (24.7) e52.7 (32.7) e58.6 (32.9) e0.4 (40.0) e19.5 (27.4) e37.6 (43.6)
Mean (95% CI)
placebo-
adjusted
change, mg/dl
— e29.7
(e41.8, e17.6)
e42.5
(e54.5, e30.4)
e55.6
(e67.6, e43.6)
— e24.8
(e38.9, e10.7)
e45.6
(e59.8, e31.4)
P-value — <0.001 <0.001 <0.001 — <0.001 <0.001
Mean (SD)
percent
change, %
e2.4 (14.4) e19.0 (12.3) e26.5 (14.9) e31.6 (18.0) 1.2 (16.6) e10.5 (15.3) e19.4 (22.1)
Mean (95% CI)
placebo-
adjusted
percent
change, %
— e15.7
(e22.1, e9.3)
e22.2
(e28.5, e15.8)
e30.1
(e36.5, e23.8)
— e13.8
(e20.9, e6.7)
e23.8
(e30.9, e16.7)
P-value — <0.001 <0.001 <0.001 — <0.001 <0.001
HDL-C
Mean (SD)
change, mg/dl
0.1 (7.0) 1.7 (7.1) 2.1 (7.5) 1.0 (7.5) e1.0 (7.4) 3.4 (9.2) 3.1 (7.7)
Mean (95% CI)
placebo-
adjusted
change, mg/dl
— 1.6 (e1.4, 4.6) 1.7 (e1.2, 4.7) 0.5 (e2.4, 3.5) — 4.5 (1.2, 7.7) 3.9 (0.6, 7.1)
P-value — 0.281 0.251 0.724 — 0.007 0.019
Mean (SD)
percent
change, %
0.8 (14.6) 3.9 (15.0) 3.9 (13.2) 2.7 (12.7) e0.4 (14.0) 7.1 (17.1) 6.9 (16.9)
Mean (95% CI)
placebo-
adjusted
percent
change, %
— 3.4 (e2.4, 9.2) 2.6 (e3.1, 8.4) 1.4 (e4.4, 7.1) — 7.7 (1.3, 14.0) 6.5 (0.2, 12.8)
P-value — 0.246 0.371 0.643 — 0.018 0.043
Triglycerides†
Median (Q1, Q3)
change, mg/dl
e18.0
(e52.0, 13.0)
e12.0
(e40.0, 9.0)
e13.0
(e43.5, 10.0)
e21.0
(e43.0, 9.0)
5.0
(e23.0, 32.0)
e9.0
(e35.0, 11.5)
e14.5
(e51.0, 13.0)
Median (Q1, Q3)
percent
change, %
e14.5
(e32.5, 11.8)
e14.1
(e28.5, 7.8)
e14.8
(e35.6, 10.7)
e18.6
(e34.5, 5.0)
3.7
(e11.3, 31.1)
e7.6
(e24.2, 14.7)
e13.8
(e32.7, 11.3)
(continued)
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Table 2
(continued)
Variable Q14 days Q28 days
Placebo
(n ¼ 47)
Bococizumab (mg) Placebo
(n ¼ 46e47)
Bococizumab (mg)
50
(n ¼ 43e44)
100
(n ¼ 42e44)
150
(n ¼ 46)
200
(n ¼ 48)
300
(n ¼ 50)
NoneHDL-C
Mean (SD)
change, mg/dl
e5.7 (26.9) e37.5 (22.4) e55.0 (32.8) e59.6 (33.2) 0.6 (38.0) e22.9 (29.1) e40.7 (44.9)
Mean (95% CI)
placebo-
adjusted
change, mg/dl
— e31.1
(e42.6, e19.6)
e44.1
(e55.6, e32.6)
e55.6
(e67.0, e44.2)
— e29.3
(e43.5, e15.1)
e48.6
(e62.7, e34.4)
P-value — <0.001 <0.001 <0.001 — <0.001 <0.001
Mean (SD)
percent
change, %
e2.3 (20.2) e28.3 (15.8) e38.5 (21.4) e44.9 (24.3) 2.8 (20.3) e17.3 (22.3) e28.7 (30.9)
Mean (95% CI)
placebo-
adjusted
percent
change, %
— e24.6
(e33.3, e15.9)
e33.2
(e41.9, e24.6)
e42.8
(e51.4, e34.2)
— e22.6
(e32.4, e12.8)
e34.7
(e44.5, e24.9)
P-value — <0.001 <0.001 <0.001 — <0.001 <0.001
Values are mean (SD), mean (95% CI), or median (Q1, Q3).
CI ¼ conﬁdence interval; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; n ¼ number of subjects treated;
SD ¼ standard deviation; TC ¼ total cholesterol; TG ¼ triglycerides.
* These values include subjects who had their bococizumab dose reduced in the weeks prior to week 12.
† The mixed model repeated measures analysis was not undertaken for triglycerides.
1216 The American Journal of Cardiology (www.ajconline.org)randomized but not treated did not have postbaseline efﬁ-
cacy measurements and so were excluded from further
analysis (1 each from the placebo, 100-mg and 150-mg
Q14 days groups). A total of 299 subjects (85% of those
treated) completed treatment. The baseline demographics
and clinical characteristics of subjects randomized to the
various treatment groups were well balanced, including
baseline LDL-C levels (Table 1).
Overall, 16%, 35%, 44%, and 39% of subjects randomized
to bococizumab 100mgQ14 days, 150mgQ14 days, 200mg
Q28 days, and 300 mg Q28 days, respectively, had their dose
reduced at any time during the study. No dose reductions
occurred in the bococizumab 50-mg Q14 days group. At the
week 10 visit (the Q14 days dosing time point before LDL-C
measurement for the primary end point), 16% of available
subjects in the bococizumab 100 mg Q14 days and 33% of
subjects in the 150-mg Q14 days dose groups had their
dose reduced (Supplementary Figure 3). At the week 8 visit
(the Q28-days dosing time point before LDL-C measurement
for the primary end point), 30% of available subjects in
the bococizumab 200 mg Q28 days and 34% of subjects in
the 300-mg Q28 days group had their dose reduced
(Supplementary Figure 3).
Starting at week 2, Q14 days and Q28 days bococizumab
dose regimens signiﬁcantly reduced LDL-C levels, and this
effect was sustained for the duration of the study. At week 12,
the primary end point ofmean absolute change from baseline in
LDL-Cwas greatest in subjects receiving bococizumab 150mg
Q14 days (Figure 2, Table 2). The placebo-adjusted mean
change from baseline in LDL-C in all subjects, including those
with dose reductions, at week 12 ranged from 34.3to53.4 mg/dl for those receiving bococizumabQ14 days and
from 27.6 to 44.9 mg/dl for those receiving bococizumab
Q28 days (Figure 3, Table 2). This corresponded to placebo-
adjusted mean percent changes from baseline of 35.0%
to 53.1% for those receiving bococizumab Q14 days
and 27.0% to 41.1% for those receiving bococizumab
Q28 days (Table 2). The PK/PD model-predicted, placebo-
adjusted mean change from baseline in LDL-C at week 12
ranged from 36.4 mg/dl for bococizumab 50 mg Q14 days
to72.2 mg/dl for bococizumab 150 mg Q14 days (Figure 3).
Before bococizumab dose reductions (up to week 6 for
Q14 days and week 8 for Q28 days), placebo-adjusted mean
reductions in LDL-C were greater than those observed at week
12 (Supplementary Figure 4). No dose reductions occurred in
the 50-mg Q14 days group, and reductions in LDL-C were
similar atweeks 8, 10, and12 (34.8,33.3, and34.3mg/dl,
respectively; Supplementary Figure 4). For the 100- and
150-mgQ14 days groups, reductions in LDL-Cwere maximal
at week 6 (59.9 mg/dl) and 8 (66.9 mg/dl), respectively
(Supplementary Figure 4). For the Q28 days regimen, changes
were greatest at week 4 for both the 200-mg (30.9mg/dl) and
the 300-mg groups (54.9 mg/dl) (Supplementary Figure 4).
Reductions in LDL-C were maintained between doses in
subjects who received bococizumab Q14 days but not in those
receiving bococizumab Q28 days (Figure 4). The individual
subject LDL-C responses for subjects receiving bococizumab
150mgQ14dayswhohad their dose reduced but did notmiss a
dose are depicted in Supplementary Figure 5, together with the
percentage of these subjects on each bococizumab dose at each
dosing visit, highlighting the effect of bococizumab dose
reduction on LDL-C levels.
Figure 3. Placebo-adjusted mean change from baseline in LDL-C at week 12. A comparison of observed* (with dose reduction), model-predicted** (assuming
no dose reduction), and Q28 days average*** (with dose reduction) data are shown. LS ¼ least squares.
Figure 4. Mean percentage change from baseline in LDL-C. Change over time is shown for the (A) Q14 days and (B) Q28 days placebo and bococizumab dose
groups.
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related reductions in noneHDL-C, which were maintained
in the Q14 days 50-mg group throughout the 24-weektreatment period. For the Q14 days 100- and 150-mg
groups, change from baseline in noneHDL-C diminished
after weeks 8 to 10, which may have been because of dose
Table 3
Percentage of subjects with all-causality and treatment-related* adverse events following randomization to placebo or bococizumab dosed every 14 days, or
placebo or bococizumab dosed every 28 days
Variable Q14 days Q28 days
Placebo
(n ¼ 49)
Bococizumab (mg) Placebo
(n ¼ 51)
Bococizumab (mg)
50
(n ¼ 50)
100
(n ¼ 51)
150
(n ¼ 49)
200
(n ¼ 50)
300
(n ¼ 51)
AEs 84% [29%] 74% [24%] 84% [31%] 82% [37%] 80% [16%] 90% [28%] 82% [33%]
Serious AEs 14% [0%] 8% [0%] 4% [0%] 8% [2%] 4% [0%] 10% [0%] 8% [0%]
Discontinuation of treatment due to AE 2% [0%] 2% [2%] 4% [0%] 10% [8%] 0% 0% 10% [4%]
Most frequent AEs (w10%)
Nasopharyngitis 12% [0%] 16% [0%] 14% [0%] 10% [0%] 14% [0%] 12% [0%] 12% [0%]
Upper respiratory tract infection 14% [0%] 8% [0%] 10% [0%] 6% [2%†] 18% [0%] 10% [2%] 6% [0%]
Diarrhea 8% [0%] 6% [0%] 8% [4%] 10% [2%] 4% [0%] 4% [0%] 8% [0%]
Urinary tract infection 6% [0%] 2% [0%] 10% [0%] 8% [2%] 2% [0%] 4% [0%] 4% [0%]
Bronchitis 8% [0%] 4% [0%] 6% [0%] 10% [0%] 6% [0%] 6% [0%] 4% [0%]
Arthralgia 4% [0%] 0% 12% [2%] 8% [0%] 6% [0%] 0% 4% [0%]
Injection site erythema 4% [4%] 4% [2%] 8% [6%] 10% [10%] 0% 8% [8%] 10% [8%]
Injection site reaction 2% [2%] 6% [6%] 2% [0%] 12% [8%] 2% [2%] 2% [2%] 10% [8%]
Gastroesophageal reﬂux disease 2% [0%] 0% 10% [0%] 4% [0%] 2% [0%] 2% [0%] 0%
Cough 10% [0%] 4% [0%] 2% [0%] 4% [0%] 2% [0%] 2% [0%] 2% [0%]
Anemia 2% [2%] 0% 10% [0%] 4% [0%] 0% 4% [0%] 0%
Values are % of subjects with all-causality [treatment-related] AEs.
n ¼ number of subjects treated.
* Investigator-determined treatment relatedness.
† Speciﬁed as viral upper respiratory tract infection.
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noneHDL-C at week 12 are provided in Table 2. Bococi-
zumab increased HDL-C at weeks 12 (Table 2) and 24. For
both bococizumab dosing intervals, statistically signiﬁcant
dose-dependent decreases in mean serum levels of total
cholesterol (Table 2) and apoB (Supplementary Table 1),
but not apoA-I (Supplementary Table 1), relative to placebo
were observed. There was a trendwise reduction in serum
triglyceride levels with respect to bococizumab dose level
across both dosing intervals tested (Table 2).
The percentage of subjects reporting AEs or serious
adverse events (SAEs) was similar across placebo and
bococizumab treatment groups (Table 3). Irrespective of
investigator-determined causality, nasopharyngitis and up-
per respiratory tract infections were the most frequently
reported all-causality AEs and showed a similar incidence in
the placebo and bococizumab groups (Table 3). The most
frequently reported treatment-related AEs were injection site
events, of which the most common was injection site ery-
thema (Table 3). One bococizumab 150 mg Q14 days
subject experienced 2 concurrent SAEs that were considered
treatment related: a viral upper respiratory tract infection
and severe dyspnea. One subject—a 74-year-old man in the
bococizumab 50-mg Q14 days treatment group—died from
an accidental head injury after a fall during the follow-up
period (57 days after last dose). This death was not
considered related to study treatment.
Overall, 14 subjects (4%) discontinued treatment because
of all-causality AEs, with more subjects in the higher than
the lower dose bococizumab groups stopping treatment
(Table 3); there was no pattern or trend in the types of AEs
that led to discontinuation of treatment. Seven subjects (2%)
discontinued treatment because of treatment-related AEs(Table 3). These were from the 50 mg Q14 days group,
urticaria (n ¼ 1); from the 150-mg Q14 days group, asthenia
and fatigue, viral upper respiratory tract infection, renal
impairment, and lip swelling (n ¼ 1 for each AE); and from
the 300-mg Q28 days group, abdominal pain and injection
site reaction (n ¼ 1 for each AE).
The incidence of AEs was similar among bococizumab-
treated subjects who had an LDL-C 25 mg/dl during the
study compared with those who did not (w80% to 90%
across most groups), and no trend was seen in the type of
AEs reported between the 2 subgroups (Supplementary
Table 2). Positive ADA titers were found in 18 of 251
bococizumab-treated subjects (7%), with one 150-mg
Q14 days bococizumab-treated subject exhibiting reduced
LDL-C lowering (0.4% of bococizumab-treated subjects). In
this subject, ADAs were detected on day 113, and subse-
quently, LDL-C levels increased toward baseline
(Supplementary Results). Otherwise, little variation was
found in LDL-C response between subjects with and
without ADAs (data not shown). The AEs reported in
subjects with ADAs were similar to those observed in
subjects without ADAs, with no signs or symptoms of hy-
persensitivity associated with positive ADA titers. Two
subjects receiving bococizumab (0.8%) experienced nonse-
rious AEs of memory loss (Supplementary Results). The
incidences of other AEs of special interest are listed in
Supplementary Table 3. Myalgia incidence across Q14 days
dose groups was placebo, 2%; bococizumab 50 mg, 2%;
bococizumab 100 mg, 4%; and bococizumab 150 mg, 0%.
For Q28 days doses, the incidence of myalgia was placebo,
2%; bococizumab 200 mg, 0%; and bococizumab 300 mg,
0%. The incidence of creatine kinase abnormalities (>2
the upper limit of normal) was similar across placebo (12%
Preventive Cardiology/Bococizumab Therapy in Statin-Treated Patients 1219to 15%) and bococizumab groups (6% to 14%). No subjects
had elevated alanine aminotransferase (ALT) or aspartate
aminotransferase levels >3 the upper limit of normal;
there were no cases of Hy’s law.
Discussion
In this phase 2b dose-ranging study of subjects with
hypercholesterolemia on stable doses of statin, compared
with placebo, bococizumab signiﬁcantly reduced LDL-C
levels across all doses. This is despite protocol-stipulated
dose reductions in a large proportion of subjects. Bococi-
zumab Q14 days and Q28 days dosing regimens produced
placebo-adjusted reductions in LDL-C at week 12 of up to
53.4 mg/dl (53.1%) for the 150-mg Q14 days dose and
44.9 mg/dl (41.1%) for the 300-mg Q28 days dose.
Bococizumab doses of up to 150 mg Q14 days and 300
mg Q28 days were generally well tolerated. Other than mild
injection site reactions with bococizumab, AEs or SAEs
were similar across placebo and bococizumab treatment
groups, and few subjects (n ¼ 7; 2%) discontinued treatment
because of treatment-related AEs. Importantly, the incidence
and type of AEs were similar among subjects in whom
LDL-C levels decreased to 25 mg/dl and those in whom
LDL-C remained >25 mg/dl, in line with a similar analysis
of evolocumab from the Open-Label Study of Long-Term
Evaluation Against LDL-C (OSLER) study.7 Positive
ADA titers were detected in w7% of bococizumab-treated
subjects, with LDL-C lowering reduced in one of these
subjects (0.4% of bococizumab-treated subjects). Recent
clinical trials of other PCSK9 inhibitors have found ADA
incidences of up to 11.5% in both phase 2 and phase 3
studies.8,9 However, the absence of standardized method-
ologies for the analysis of ADAs makes a meaningful
comparison of ADA rates across disparate studies or anti-
bodies problematic.10 A more comprehensive assessment of
the proportion of patients who develop ADAs and the
impact these may have on the LDL-Celowering efﬁcacy
and safety of bococizumab, and the wider PCSK9 inhibitor
class, will be evaluated in larger longer term phase 3 trials.
Although the lower levels of LDL-C achievable with
currently available lipid-lowering therapies do not appear to
be harmful,11 the safety of the very low levels of LDL-C
achievable with PCSK9 inhibitors, particularly when sus-
tained over a prolonged period, is unclear,5,11 although
recently published safety data from longer term trials of
evolocumab are encouraging.7,12 Previous epidemiologic
studies and data from earlier statin trials suggested an asso-
ciation between lower levels of LDL-C and increased risk of
cancer, hemorrhagic stroke, and noncardiac death5,11: an as-
sociation that has not been supported by subsequent outcome
studies and large meta-analyses.11,13 Concerns have also been
raised regarding possible cognitive symptoms associated with
very low LDL-C levels.5,14 In this study, 2 subjects receiving
bococizumab experienced a nonserious AE of memory loss;
however, these subjects were both receiving concomitant
medications (a statin and/or zolpidem tartrate) previously
associated with memory loss (Supplementary Results). The
phase 3 clinical trials of PCSK9 inhibitors will demonstrate
whether prolonged very low LDL-C values (or PCSK9
inhibition) have any impact on cognition.The advent of PCSK9 inhibitors has meant that LDL-C
levels of 25 mg/dl, and even <10 mg/dl, can be ach-
ieved within a few weeks of the ﬁrst dose. Owing to the
limited data available on the physiological effects of very
low levels of LDL-C, a unique aspect of this study was the
protocol-stipulated bococizumab dose reductions in subjects
with persistent LDL-C levels 25 mg/dl. Up to 44% of
subjects receiving higher doses of bococizumab had dose
reductions because of LDL-C levels 25 mg/dl, indicating
that some subjects who showed the greatest response to
bococizumab had their dose reduced (Supplementary
Figure 6), thus tempering individual LDL-C responses
(Supplementary Figure 5) and the overall group mean LDL-
C reductions observed at week 12. Reductions in LDL-C
were greater before dose reduction: for the 100- and
150-mg Q14 days dose groups, LDL-C reductions at weeks
6 and 8 were w13 to 15 mg/dl greater than those at week
12; for the 200- and 300-mg Q28 days dose groups, the
respective LDL-C reductions at week 4 were w3 and
w10 mg/dl greater than those at week 12. However, factors
other than dose reduction, such as missed doses of study
medication, may have had an effect on the outcomes of this
study (Supplementary Figure 6). A population PK/PD
model was used to predict the expected LDL-C response
assuming no dose reductions or missed doses. This analysis
suggested that LDL-C would have been lowered at week 12
by an additional w2 to 19 mg/dl with bococizumab
Q14 days and by an additional w11 to 13 mg/dl with
bococizumab Q28 days, in the absence of dose reductions or
missed doses.
Recent studies have highlighted the importance of stable,
sustained reductions in cardiovascular risk factors such as
blood pressure15 and LDL-C16 for optimizing cardiovascular
event reduction. For LDL-C, an analysis of the Treating to
New Targets trial demonstrated that visit-to-visit variability
in LDL-C was an independent predictor of cardiovascular
risk.16 Each 1-SD increase in LDL-C variability, measured as
the average absolute difference between successive values,
increased the risk of any coronary event by 16% and any
cardiovascular event by 11%, independent of statin dose and
achieved LDL-C.16 This is a consideration with the dosing of
PCSK9 mAbs, where high-dose monthly regimens can pro-
duce substantial ﬂuctuations in LDL-C levels between doses,
leading to large visit-to-visit LDL-C variability,17e20 as
conﬁrmed in this study. The magnitude of LDL-C reductions
from baseline achieved with bococizumab—up tow60% at
week 8 with 150 mg Q14 days and up tow74% at the week 2
nadir with 300 mg Q28 days—was comparable with that
reported for other PCSK9 inhibitors currently in clinical
development.9,17e22 Although greater maximal reductions in
LDL-C were seen with higher doses of bococizumab
administered Q28 days, these reductions were not as well
maintained between doses. After the decrease in LDL-C
levels 2 weeks after administration of each Q28 days boco-
cizumab dose, LDL-C levels gradually increased in the
2 weeks post-nadir, resulting in a “saw-tooth” pattern
(Figure 4) that has also been observed with monthly dosing of
evolocumab17,18 and alirocumab.19,20 Lower doses of boco-
cizumab administered Q14 days eliminated the cycle of
LDL-C ﬂuctuation seen with monthly dosing while still
resulting in signiﬁcant LDL-C reductions (Figure 4). The
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dosing regimens is unknown. In the present study, LDL-C
levels at week 2 were reduced by w70% from baseline
with high-dose Q28 days bococizumab therapy, with LDL-C
values falling to 25 mg/dl in w40% of subjects in the
2 weeks after the ﬁrst dose. Together, these observations
support a Q14 days rather than a Q28 days bococizumab
dosing regimen for phase 3 studies.
The achievement of substantial reductions in LDL-C levels
after PCSK9 inhibition is likely to be of clinical beneﬁt,
particularly in patients at high cardiovascular risk who
continue to have elevated LDL-C on maximally tolerated
statin therapy. However, there are challenges associated with
using a new therapy, such as PCSK9 inhibitors, that can lead
to very low levels of LDL-C. First is a reliable method for
measuring and reporting very low LDL-C values by clinical
laboratories. Although the Friedewald equation has been
routinely used to calculate LDL-C for >40 years, it can
underestimate low levels of LDL-C compared with direct
measurement after ultracentrifugation (used in this study for
LDL-C levels 25 mg/dl).23,24 Newer, more accurate
methods for calculation of LDL-C from a standard lipid proﬁle
have been proposed, most recently by Martin et al.25 External
validation of this new method may provide clinicians with a
reliable and inexpensive method to assess LDL-C at the very
low levels likely to be achieved with PCSK9 inhibition.
Signiﬁcant rapid reductions in LDL-C levels with
PCSK9 inhibitors will also present physicians with a choice
between starting with a low dose and up-titration, if
necessary, or with high doses and subsequent dose reduction
if required or ignoring LDL-C levels after initiation of
therapy. Intensive initial therapy is often preferred to reduce
cardiovascular outcomes, particularly in high-risk patients,
and provides an argument for high initial doses. The LDL-C
level at which dose reduction is triggered is crucial to attain
maximal clinical beneﬁt. This study used a threshold LDL-C
of 25 mg/dl for dose reduction; however, LDL-C values
25 mg/dl were frequently achieved, and dose reduction
occurred frequently and limited efﬁcacy. LDL-C levels of
25 mg/dl were not associated with harm in this study and
do not appear to be associated with harm in trials of other
PCSK9 inhibitors conducted to date.5,7,14 Hence, future
studies may need to consider lowering the LDL-C threshold
at which dose reduction is initiated (e.g., 10 mg/dl).
The clinical efﬁcacy and safety of PCSK9 inhibitors look
promising based on the results of phase 3 lipid-lowering
trials.9,12,21,22 However, the results of cardiovascular
outcome trials are needed to conﬁrm the long-term safety of
PCSK9 inhibitors and the efﬁcacy for reducing cardiovas-
cular events. Although this phase 2 dose-ranging study
excluded subjects with recent cardiovascular events and did
not require a high cardiovascular risk status for entry (and,
thus, may not represent a patient population at highest car-
diovascular risk), the bococizumab phase 3 Studies on
PCSK9 Inhibition and the Reduction of vascular Events
(SPIRE) program consists of additional trials assessing the
lipid-lowering efﬁcacy of bococizumab and 2 cardiovascu-
lar outcome studies that include high-risk patients. SPIRE-1
(NCT01975376) will assess whether lowering LDL-C to
levels well below previously recommended targets will lead
to further reduction in cardiovascular events. This studyincludes high-risk patients with baseline LDL-C levels 70
to <100 mg/dl. SPIRE-2 (NCT01975389) will evaluate the
efﬁcacy and safety of bococizumab in a range of high-risk
patients who have not achieved LDL-C levels <100 mg/dl
despite high-dose statin therapy or who are partially or
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